Viewing Protocol Section

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT00152971
Ignite Creation Date: 2024-05-05 @ 11:52 AM
Last Modification Date: 2024-10-26 @ 9:14 AM
Study NCT ID: NCT00152971
Protocol Section: NCT00152971
Start Identification Module Data
Expand Identification Module Data
Brief Title: Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism VTE Post Total Knee Replacement
Official Title: A Phase III Randomized Parallel-group Double-blind Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens 75mg Day 1 Followed by 150 mg Day 2-completion and 110 mg Day 1 Followed by 220 mg Day 2-completion of Dabigatran Etexilate Administered Orally Capsules Compared to Enoxaparin 30 mg Twice a Day Subcutaneous for 12 - 15 Days in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Knee Replacement Surgery
Acronym: None
Organization: Boehringer Ingelheim
Organization Class: INDUSTRY
Organization Study ID: 116024
Start Status Module Data
Status Verified Date: 2014-04
Overall Status: COMPLETED
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: Boehringer Ingelheim
Lead Sponsor Class: INDUSTRY
Lead Sponsor: Boehringer Ingelheim
Start Oversight Module Data
Description Module:
Study Last Update Post Date Type(Status Module):
Attachment: Upload